CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Authors
Walls, G. M.Oughton, J. B.
Chalmers, A. J.
Brown, S.
Collinson, F.
Forster, M. D.
Franks, K. N.
Gilbert, A.
Hanna, G. G.
Hannaway, N.
Harrow, S.
Haswell, T.
Hiley, C. T.
Hinsley, S.
Krebs, Matthew G
Murden, G.
Phillip, R.
Ryan, A. J.
Salem, Ahmed
Sebag-Montefoire, D.
Shaw, P.
Twelves, C. J.
Walker, K.
Young, R. J.
Faivre-Finn, C.
Greystoke, A.
Affiliation
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK.Issue Date
2020
Metadata
Show full item recordAbstract
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.Citation
Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, et al. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol. 2020;25:61-6.Journal
Clinical and Translational Radiation OncologyDOI
10.1016/j.ctro.2020.09.006PubMed ID
33072895Additional Links
https://dx.doi.org/10.1016/j.ctro.2020.09.006Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ctro.2020.09.006
Scopus Count
Collections
Related articles
- Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
- Authors: Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A
- Issue date: 2022 Oct
- Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
- Authors: Doyen J, Poudenx M, Gal J, Otto J, Guerder C, Naghavi AO, Gérard A, Leysalle A, Cohen C, Padovani B, Ianessi A, Schiappa R, Chamorey E, Bondiau PY
- Issue date: 2018 May
- Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE.
- Authors: Walker K, Hinsley S, Phillip R, Oughton JB, Murden G, Chalmers AJ, Faivre-Finn C, Greystoke A, Brown SR, CONCORDE Investigators
- Issue date: 2022 Nov
- Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
- Authors: Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, König J, Grosu AL, PET-Plan study group
- Issue date: 2020 Apr